Literature DB >> 8275088

Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours.

E Friedman1, P V Gejman, G A Martin, F McCormick.   

Abstract

GTPase Activating Protein (GAP) is involved in down-regulating normal ras proteins and in the signal transduction pathway of some growth factors. We have screened 188 human tumours for mutations in the catalytic domain and at the C terminal SH2 region GAP. Three nonsense mutations in basal cell carcinomas were detected in the SH2 region and no mutations could be demonstrated in the catalytic domain. We conclude that mutations in the SH2 region of GAP may play a role in tumorigenesis and that inactivating mutations of the GAP catalytic domain do not contribute to tumour development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8275088     DOI: 10.1038/ng1193-242

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  12 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

2.  Testing for Ancient Selection Using Cross-population Allele Frequency Differentiation.

Authors:  Fernando Racimo
Journal:  Genetics       Date:  2015-11-23       Impact factor: 4.562

Review 3.  SH2 domain-containing signaling proteins in human breast cancer.

Authors:  R J Daly
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

4.  Detection of RASA1 mutations in patients with sporadic Sturge-Weber syndrome.

Authors:  Qin Zhou; Jia-wei Zheng; Xiu-juan Yang; Hui-jun Wang; Duan Ma; Zhong-ping Qin
Journal:  Childs Nerv Syst       Date:  2010-09-07       Impact factor: 1.475

Review 5.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

6.  Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.

Authors:  Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula
Journal:  Am J Hum Genet       Date:  2003-11-24       Impact factor: 11.025

7.  Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers.

Authors:  Hongchuan Jin; Xian Wang; Jianming Ying; Ada H Y Wong; Yan Cui; Gopesh Srivastava; Zhong-Ying Shen; En-Min Li; Qian Zhang; Jie Jin; Sabine Kupzig; Anthony T C Chan; Peter J Cullen; Qian Tao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

8.  CAERUS: predicting CAncER oUtcomeS using relationship between protein structural information, protein networks, gene expression data, and mutation data.

Authors:  Kelvin Xi Zhang; B F Francis Ouellette
Journal:  PLoS Comput Biol       Date:  2011-03-31       Impact factor: 4.475

9.  RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.

Authors:  Jun Kawasaki; Sandrine Aegerter; R Dawn Fevurly; Akiko Mammoto; Tadanori Mammoto; Mustafa Sahin; John D Mably; Steven J Fishman; Joanne Chan
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

10.  Semi-supervised prediction of SH2-peptide interactions from imbalanced high-throughput data.

Authors:  Kousik Kundu; Fabrizio Costa; Michael Huber; Michael Reth; Rolf Backofen
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.